Multiplex Apolipoprotein Panel Improves Cardiovascular Event Prediction and Cardiovascular Outcome by Identifying...

Area of Science:

• Cardiovascular Medicine
• Biochemistry
• Precision Medicine

Background:

• Residual cardiovascular risk persists despite statin therapy and optimal lipid levels.
• Traditional risk scores are insufficient for predicting outcomes in acute coronary syndrome (ACS) patients.
• Apolipoproteins offer potential for enhanced risk stratification and personalized treatment strategies.

Purpose of the Study:

• To evaluate the prognostic utility of a 9-plex apolipoprotein panel in ACS patients on statins.
• To assess the panel's ability to predict treatment benefit from alirocumab, a PCSK9 inhibitor.
• To enable precision medicine approaches for cardiovascular risk management.

Main Methods:

• Analysis of baseline serum samples from 11,843 ODYSSEY OUTCOMES trial participants using mass spectrometry.
• Measurement of nine key apolipoproteins (Apo(a), ApoA-I, ApoA-II, ApoA-IV, ApoB, ApoC-I, ApoC-II, ApoC-III, ApoE).
• Logistic regression models used to estimate major adverse cardiovascular events (MACE) and all-cause death, comparing apolipoprotein, lipid, and combined panels.

Main Results:

• The apolipoprotein panel demonstrated superior prognostic performance for MACE (AUC 0.648) and all-cause death (AUC 0.699) compared to the lipid panel (AUC 0.579 and 0.599, respectively).
• Adding the apolipoprotein panel significantly improved the predictive accuracy of the conventional lipid panel (P<0.0001).
• Higher MACE risk predicted by the apolipoprotein panel correlated with greater treatment benefit from alirocumab.

Conclusions:

• A multiplex apolipoprotein panel significantly enhances prediction of MACE and all-cause death in post-ACS patients on statins, outperforming traditional lipid panels.
• The apolipoprotein panel can predict treatment response to alirocumab, supporting its role in precision cardiovascular medicine.
• Further validation is required, but this approach holds promise for improved disease prediction and patient management.